newsfilter
← Latest News
GlobeNewswire·

Alector Reports First Quarter 2025 Financial Results and Provides Business Update

Topline data from pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN on track for Q4 2025 Completed enrollment in PROGRESS-AD Phase 2 clinical trial of AL101 in early Alzheimer's disease Continuing to